We have previously shown that the adenovirus E1A oncogene can reactivate the cell cycle in terminally dierentiated cells. Current models imply that much or all of this E1A activity is mediated by the release of the E2F transcription factors from pocket-protein control. In contrast, we show here that overexpression of E2F-1, E2F-2 and E2F-4, or a chimeric E2F-4 tethered to a nuclear localization signal cannot reactivate postmitotic skeletal muscle cells (myotubes). This is not due to lack of transcriptional activity, as demonstrated on both a reporter construct and a number of endogenous target genes. Although cyclin E was strongly overexpressed in E2F-transduced myotubes, it lacked associated kinase activity, possibly explaining the inability of the myotubes to enter S phase and accumulate cyclin A. Although E2F is not sucient to trigger DNA synthesis in myotubes, its activity is necessary even in the presence of E1A, as dominant-negative DP-1 mutants inhibit E1A-mediated cell cycle reentry. Our data show that, to reactivate myotubes, E1A must exert other functions, in addition to releasing E2F. They also establish mouse myotubes as an experimental system uniquely suited to study the most direct E2F functions in the absence of downstream cell cycle eects.
Introduction
Terminal dierentiation can be de®ned as a state in which a cell has acquired functional specialization and has lost its ability to proliferate. Such loss is physiologically irreversible and constitutes the hallmark of terminal dierentiation. The majority of the cells in an adult mammal are terminally dierentiated (TD). One example of terminal dierentiation is provided by skeletal muscle cells. Undierentiated myoblasts can proliferate, both in vitro and in vivo, in response to growth factors. In vitro, growth factor withdrawal induces myoblasts to cease proliferating irreversibly and begin to express muscle-speci®c genes, thus becoming myocytes. Myocytes, in turn, fuse into multinucleated, syncitial structures called myotubes. Myotubes are TD cells (Okazaki and Holtzer, 1966) that are unable to proliferate in response to growth factors and/or expression of retroviral oncogenes or positive regulators of the cell cycle (Tiainen et al., 1996a) .
In contrast, DNA tumor virus oncogenes such as the polyoma and SV40 T antigens are able to reactivate the cell cycle in TD cells (Fogel and Defendi, 1967; Yae and Gershon, 1967; Endo and Nadal-Ginard, 1989; Cardoso et al., 1993) . In particular, we have shown that the adenovirus oncogene E1A can induce TD myotubes to synthesize DNA and divide (Crescenzi et al., 1995a,b; Tiainen et al., 1996b) . E1A displays this activity both as a single, transfected gene (Tiainen et al., 1996a) , and in the context of the whole adenovirus (Tiainen et al., 1996b) . In the latter case, the virus serves as a very ecient vehicle to transduce E1A because of its ability to infect a great variety of cells across a wide range of species, irrespective of their proliferation status. Indeed, this¯exibility has been exploited to demonstrate that E1A can reactivate the cell cycle in other types of TD cells, including adipocytes and myocardiocytes (Crescenzi et al., 1995a; Kirshenbaum and Schneider, 1995) .
E1A exerts its eects on cell proliferation by binding a number of cellular proteins, including the transcriptional cofactor p300 and, through separate domains, the retinoblastoma (Rb) family of`pocket' proteins (Harlow et al., 1986; Whyte et al., 1989; Wang et al., 1993) . We have shown that the former function is dispensable for reactivating the cell cycle in myotubes. On the contrary, the ability of mutant E1A proteins to bind pRb and/or its relatives p107 and p130 strongly correlates with their capacity to trigger DNA synthesis in postmitotic cells (Tiainen et al., 1996b) . Current models largely hold that E1A activates DNA synthesis by binding pRb family members, thus releasing transcription factors of the E2F family (E2F-1 through -5) (Weinberg, 1995) . This, in turn, would result in the transcriptional upregulation of a host of genes that are regulators or eectors of DNA synthesis. Such E2F target genes include, among others, DNA polymerase a, B-myb, the E and A cyclins, PCNA, and DHFR (Dyson, 1998) . E2F acts on the promoters of some of these genes as a repressor when bound by a pocket protein. Alternatively, it can act as a transcriptional activator when freed from pocket protein control. In both of these capacities, in order to bind DNA, the E2Fs must form heterodimers with one of the products of the two DP genes (Dyson, 1998; Helin, 1998) . This model implies that overexpression of E2F should substitute for E1A in reactivating the cell cycle. In this view, overexpressing E2F would directly upregulate promoters on which E2F mainly acts as a transcriptional activator. Conversely, an excess of free E2F should compete with E2F/pocket-protein complexes for those promoters that are mainly suppressed by the binding of these complexes. Indeed, in keeping with this model, forced expression of various E2F isoforms has been shown to activate the cell cycle in serum-starved, quiescent cells (Johnson et al., 1993; Shan and Lee, 1994; Lukas et al., 1996) . In some experimental settings, E2F has been shown to trigger DNA synthesis even in the absence of signi®cant cyclin-dependent kinase activitites (DeGregori et al., 1995) . Despite impressive evidence in favor of a pivotal role of the E2Fs in cell cycle control, it is not ®rmly established whether the E2F family is indispensable for S phase entry (Dyson, 1998; Helin, 1998) . In fact, it has been reported that, at least in some settings, overexpression of cyclin E can overcome the absence of E2F transcriptional activity (Lukas et al., 1997) .
We and others have previously shown that overexpression of E2F is unable to drive TD mouse myotubes into S phase (Tiainen et al., 1996a; Puri et al., 1998) . However, these experiments left open the question whether E2F exerts any functional activities in TD muscle cells. Thus, we wished to assess the functionality of E2F in the muscle environment. If in myotubes E2F, though unable to activate DNA synthesis, displayed the same capabilities as in other cells, it would follow that E1A triggers S phase not only by releasing E2F but also through additional mechanisms. A complementary question was whether E2F is necessary at all for E1A-mediated S phase activation in myotubes.
To address these issues, we have overexpressed E2F/ DP proteins in myotubes, con®rming that no DNA synthesis was elicited. This was not due to the absence of E2F transcriptional activity, as a number of its target genes were upregulated, including cyclin E. However, at variance with E1A, E2F/DP triggered accumulation of the kinase inhibitor p27, which associated with cyclin E complexes. Such complexes lacked kinase activity, cyclin A was not upregulated, and DNA synthesis did not occur. Thus, in order to induce TD myotubes to proliferate, E1A must exert actions other than freeing E2F. However, expression of dominant-negative DP mutants showed that E2F activity is required for S phase entry even in the presence of E1A.
Results

E2F does not activate DNA synthesis in TD myotubes
Initial experiments were designed to con®rm that E2F-1 is unable to reactivate the mitotic cycle in mouse myotubes and determine whether other members of the E2F family are equally ineective. Murine myotubes derived from the C2C12 myoblast cell line or primary satellite cells were infected with AdE2F-1, a recombinant adenovirus carrying E2F-1. To verify the expression of the protein, lysates of proliferating myoblasts or TD myotubes infected with AdE2F-1 or the d1312 control virus were analysed by Western blotting. Figure 1 shows that the exogenous E2F-1 levels far exceeded the endogenous ones in myotubes and also those found in proliferating myoblasts. To rule out the possibility that DP-1 might be limiting in our conditions, in some experiments TD myotubes were also transfected with an expression vector for DP-1 or infected with the DP-1-carrying recombinant adenovirus AdDP-1. DNA synthesis was monitored by BrdUrd incorporation in the 72 h following transfection/infection. In a large number of experiments E2F-1, alone or in combination with DP-1, failed to reactivate DNA synthesis in myotubes.
Similar experiments were performed with viruses carrying E2F-2 or E2F-4. None of these infections elicited DNA synthesis, while the E1A-carrying dl520 adenovirus reactivated the myotubes in a dosedependent fashion (multiplicities of infection (MOIs) from 100 ± 1000 induced DNA synthesis in 20 ± 595% of the myotubes). Since the prevailing E2F form in myotubes is E2F-4 (Puri et al., 1997) , it was conceivable that E1A reactivates myotubes by releasing this speci®c protein which might exert activities possibly not shared by its relatives. To test this possibility, we transfected into satellite-cell derived myotubes a plasmid encoding an E2F-4 chimeric protein carrying a nuclear localization signal (E2F-4-NLS) (Muller et al., 1997) . The NLS ensures that the protein is carried into the nucleus, since wild type E2F-4 is cytoplasmic (Magae et al., 1996; de la Luna et al., 1996; Lindeman et al., 1997; Muller et al., 1997; Verona et al., 1997) . Similar to the other E2Fs, E2F-4-NLS did not activate S phase in myotubes (data not shown).
E2F has transacting activity in TD myotubes
The persistent failure to induce DNA synthesis in myotubes through E2F expression raised the possibility that in this cellular environment E2F might be transcriptionally silent. To test this hypothesis, the E2F-responsive contruct pGL3TATAbasic6XE2F-Luc (E2F-luc) or the control plasmid pGL3TATAbasic (TATA-basic) was transiently transfected into C2C12 myoblasts. The transfected cells were induced to dierentiate into myotubes and puri®ed by Ara-C Figure 1 E2F-1 protein expression. E2F-1 protein levels were analysed by Western blotting on total cellular lysates of proliferating C2C12 myoblasts or TD myotubes infected with the recombinant AdE2F-1 or the control dl312 adenovirus E2F activity in skeletal muscle cells D Pajalunga et al treatment (see Materials and methods). The myotubes were then infected with AdE2F-1 or AdE2F-4. Despite some variability, AdE2F-1 consistently showed transacting capacity on the reporter construct in several independent experiments (Figure 2a ). Conversely, AdE2F-4 did not signi®cantly activate transcription, consistent with its reported cytoplasmic localization. To verify that the E2F-4-NLS protein is transcriptionally active in myotubes, the corresponding expression vector was cotransfected along with the E2F-luc reporter in myoblasts which were then induced to dierentiate in the presence of Ara-C. As shown in Figure 2b , luciferase expression elicited in myotubes by E2F-4-NLS was similar to that induced by an E2F-1 plasmid. The addition of a DP-1-encoding adenovirus increased somewhat the transcriptional activity of E2F-1 and E2F-4-NLS ( Figure 2b ). Altogether, these experiments indicate that E2F possesses a signi®cant transacting capacity in myotubes.
We then asked whether E2F-mediated transactivation in myotubes is exerted on endogenous promoters as well. RNA extracted from C2C12 myotubes infected with AdE2F-1 or the control virus dl312 was analysed. For reference purposes, serum-starved, undierentiated, quiescent C2Q16 myoblasts were infected with the same viruses and subjected to the same analysis. As shown in Figure  3a , transcription of the E2F-regulated PCNA, cyclin E, and B-myb genes was increased by AdE2F-1 infection, most markedly at 48 h p.i. These increases were comparable to those obtained in quiescent myoblasts, which are readily induced to enter S phase by E2F-1 (Tiainen et al., 1996a) . On the contrary, E2F-1 strongly upregulated expression of another target gene, cyclin A, only in myoblasts but very little if at all in myotubes. Thus E2F-1, when expressed in myotubes, not only displays transcriptional activity on an arti®cial promoter, but also upregulates several E2F target genes, with the notable exception of cyclin A.
Protein products of E2F target genes in E2F-1 overexpressing myotubes
To assess whether the transcriptional upregulation of some E2F-responsive genes in myotubes is re¯ected by the accumulation of their respective products, we analysed total protein extracts of myotubes or undierentiated, quiescent myoblasts infected with AdE2F-1 or dl312. Figure 3b shows that the cyclin E and B-myb protein levels were increased both in myotubes and myoblasts. Although B-myb levels were signi®cantly lower in AdE2F-1-infected myotubes than in myoblasts, this cannot explain the inability of E2F-1 overexpression to mimic E1A in myotubes since B-myb is modestly elevated also in E1A-reactivated TD muscle cells (Tiainen et al., 1996b) . In agreement with the low levels of cyclin A mRNA, the corresponding protein was only barely detectable at 24 h p.i. in E2F-1-infected myotubes. In fact, immuno¯uorescent staining of cyclin A in E2F-1 expressing myotubes showed that the cyclin was only detectable in the contaminating myoblasts, but not in myotubes ( Figure  3c ).
Cyclin E complexes are inhibited in E2F-overexpressing myotubes
In agreement with our previous observations (Tiainen et al., 1996b) , cyclin E was expressed in the dl520-or AdE2F-1-infected myotubes at much higher levels than in proliferating myoblasts ( Figure  4a ). Since cyclin A transcription depends on cyclin E-associated kinase activity, the lack of signi®cant accumulation of cyclin A mRNA in AdE2F-1-infected myotubes suggested that this kinase activity might be low in these cells. Indeed, kinase assays on a b
Figure 2 E2F-1 transacting capacity on a reporter construct. Proliferating C2C12 myoblasts were transiently transfected with the E2F-responsive construct E2F-luc or the control plasmid TATA-basic. The cells were then induced to dierentiate in the presence of Ara-C. After 72 h, the puri®ed TD myotubes were infected with (a) recombinant adenoviruses carrying E2F-1 or -4 (AdE2F-1 or AdE2F-4) or with the dl520 virus. (b) In similar experiments, proliferating C2C12 myoblasts were transiently cotransfected with the reporter constructs along with an expression vector for E2F-1 or E2F-4-NLS. The cells were then induced to dierentiate. Where indicated, after 72 h the TD myotubes were subjected to infection with a recombinant adenovirus carrying DP-1 (AdDP-1). Luciferase activity was detected in TD myotubes at 48 h from the infections cyclin E complexes immunoprecipitated from AdE2F-1-or dl520-infected myotubes revealed that, despite the powerful overexpression of cyclin E, AdE2F-1 myotubes were almost devoid of associated kinase activity (Figure 4b ). In sharp contrast, E1A-expressing, dl520-infected myotubes showed a far higher kinase activity than found in proliferating, undierentiated myoblasts ( Figure 4b ). As pRb is a known substrate for cyclin E-regulated kinase(s), we looked at the phosphorylation status of this pocket protein. In strict correspondence with the presence of cyclin E-associated kinase activity, Western blots for pRb revealed the presence of slowly migrating, hyperphosphorylated bands in proliferating cells and in dl520-infected myotubes, but not in the E2F-1-overexpressing ones (Figure 4b) . Next, we asked whether cyclin-dependent-kinase inhibitors (CKIs) might be present in the cyclin E complexes, possibly inhibiting their activities. Immunoprecipitations were performed on AdE2F-1-and dl520-infected myotubes with an anti-cyclin E antiserum. The precipitated complexes were analysed by Western blotting for the presence of the CKIs p27 and p21. Figure 5a shows that p27 was abundant in immunoprecipitates from cells infected with either virus. However, E2F-1-expressing cells showed a time-dependent increase in the amount of immunoprecipitable p27, which was not observed in the dl520 myotubes. Precipitates from control myotubes (uninfected and infected with the empty J-pCA13 virus) showed very little p27, which was visible on longer exposures, in agreement with the much lower amount of cyclin E they contained. p21 was equally present in protein complexes from both AdE2F-1-and dl520-infected myotubes during the whole time course, indicating that the time-dependent increase in the amount of p27 present in E2F-1 precipitates was speci®c (Figure 5a) . Accordingly, the amount of coimmunoprecipitated cdk2, the principal kinase associated with cyclin E, did not vary signi®cantly during the time frame considered.
To assess the overall expression of p27 in AdE2F-1-and dl520-infected myotubes, we analysed total cellular lysates for this CKI. Figure 5b shows that cells infected with either virus displayed a progressive increase in the total amount of p27, even though AdE2F-1 myotubes expressed somewhat higher levels of p27 at all time points. Conversely, p21 levels were not appreciably modi®ed by any of the infections. These results indicate that accumulation of p27 is promoted more eectively by E2F-1 than E1A in myotubes, and that such accumulation is the result of a p27-speci®c mechanism(s).
E2F is necessary for E1A-mediated reactivation of the cell cycle in myotubes
Having shown that E2F cannot substitute for E1A in reactivating TD myotubes, we addressed the question whether E2F transcriptional activity is nonetheless necessary to mediate such reactivation. We exploited two dominant-negative mutants of DP-1 (DP-1
and DP-1 127 ± 410 ) capable of inhibiting progression of the cell cycle in human osteosarcoma cells and rat embryo ®broblasts Lukas et al., 1997) . The ability of these mutants to inhibit DNA synthesis in myoblasts was veri®ed by transient transfection of the respective expression vectors into C2C12 myoblasts. Incorporation of BrdUrd into cells expressing DP-1 mutants was then assessed between 40 and 48 h after transfection. Table 1 only about one-third of the myoblasts expressing either DP-1 mutant incorporated BrdUrd, while wild-type DP-1 did not inhibit DNA synthesis. When expressed in myotubes before dl520 infection, the same mutants inhibited E1A-induced DNA synthesis to a signi®cant extent. If E2F activity is necessary for E1A to trigger S phase in myotubes and the DP-1 mutants are able to sequester and block all the available E2F in a given cell, it follows that increasing the amount of E1A expressed in that cell should have no eect on the cell's ability to incorporate BrdUrd. Figure 6 shows that this is indeed the case, as increasing up to ®vefold the MOI for dl520 infection did not signi®cantly augment the percentage of myotubes synthesizing DNA. Taken together, these results indicate that the activity of E2F, though insucient per se to trigger DNA synthesis in TD myotubes, is necessary for E1A to reactivate the cell cycle in these cells. This conclusion is reinforced by the ®nding that AdE2F-1-infection synergizes with low-multiplicity dl520 infection (MOI 100) of myotubes to increase the reactivated TD cells from 42 ± 75%. This last result con®rms that E1A-driven reactivation of myotubes is mediated by E2F, which becomes limiting in case of suboptimal E1A expression.
An as yet unidenti®ed activity of E1A is necessary for cell cycle reactivation in myotubes
The above results suggest either that binding pRb is not sucient for E1A to activate DNA synthesis in myotubes or that the release of E2F is not the sole functionally signi®cant consequence of such binding.
To test this interpretation, we tried to complement the E1A 928 mutant, which bears a single amino acid substitution in the conserved domain 2 (Cys 124 to Gly), cannot bind pRb, and does not trigger DNA synthesis in myotubes. We reasoned that if the 928 mutation impairs E1A only in its ability to bind pRb and if the only result of this interaction is the freeing of E2F, then E2F-1 overexpression should complement this mutant and reactivate the cell cycle in TD muscle cells. However, in a number of experiments, myotubes infected with the 12S.928 virus and transfected with pCMV-E2F-1 (data not shown) or coinfected with AdE2F-1 (Table 2) never undertook DNA synthesis. Table 2 shows that AdE2F-1 failed to complement the 928 mutant even at a sixfold higher MOI than used in all other experiments.
One possible interpretation descending from this result is that E1A possesses a second function which is necessary for cell cycle reactivation in myotubes and that this putative function maps at least in part to the conserved domain 2. The recent report that a previously unknown function of E1A is necessary to overcome a cell cycle block imposed by p27 (Alevizopoulos et al., 1998) prompted us to determine whether such function is also required in our TD system. Mouse satellite cell-derived myotubes were thus transfected with expression vectors carrying the E1A D26 ± 33 mutant, which lacks the p27-overcoming activity, or wild-type E1A. In these experiments the E1A D26 ± 33 mutant reactivated TD, multinucleated myotubes at least 50% as eciently as wild-type E1A, demonstrating that the p27-overcoming activity is not required for myotube reactivation.
Discussion
E2F cannot reactivate the cell cycle in myotubes despite a signi®cant transcriptional activity and, most important, its ability to activate a number of endogenous target genes and promote the expression of the corresponding proteins. In experiments with an E2F reporter construct, the E1A control showed a twofold higher activity than E2F (Figure 2a ). This is likely explained by the fact that E1A disrupts inhibitory E2F/ Transfected myoblasts were induced to dierentiate immediately after transfection, infected with dl520 72 h later (MOI 300), and stained for hemagglutinin and BrdUrd after 48 h from infection. Hemagglutininpositive cells were scored for BrdUrd incorporation Figure 6 Interference of a dnDP-1 mutant with E1A-induced DNA synthesis is independent of E1A levels. Proliferating C2C12 myoblasts were transiently transfected with the pCMVHADP-1 D103 ± 126 plasmid. The cells were then shifted to DM and puri®ed TD myotubes were infected with dl520 at increasing MOIs. Entry into S phase was monitored by indirect immuno¯uorescence for BrdUrd incorporation. The reported values are averages with standard deviations of three independent experiments pocket-protein complexes. Conversely, in E2F-overexpressing cells, such complexes continue to exist and compete with the free factor. However, in the same conditions, E2F promotes the expression of endogenous, responsive genes at least as well as E1A (Figure 4a and unpublished data). E2F activity, although insufficient, is indeed required for cell cycle reactivation even in the presence of E1A, as demonstrated by the inhibitory activity of dominant-negative mutants of DP-1. However, cell cycle reactivation by E1A clearly requires mechanisms in addition to E2F release. At least two, general, non-mutually exclusive hypotheses can be made. E1A might exert a function, completely distinct from pRb binding, which is necessary for cell cycle reactivation in myotubes. Alternatively or in conjunction, pRB binding might result not only in E2F release but also in the activation of a second pathway. In the ®rst view, the putative E1A function should map to the conserved region 2, as it is abrogated by the 928 mutation. Such function is not that described by Alevizopoulos et al. (1998) , since the E1A D26 ± 33 mutant is still capable of cell cycle reactivation in myotubes. One way of picturing the second hypothesis is to suppose that the binding of E1A to pRb frees other (transcription) factors besides E2F, one of which might be absolutely required for cell cycle reactivation in the skeletal muscle system. Dierent from many other systems, skeletal muscle cells cannot be forced into S phase by E2F overexpression, underscoring the peculiar cell cycle control operating in these TD cells. This makes the skeletal muscle a unique experimental system for studying a subset of E2F activities, presumably the most direct ones, in the absence of cell cycle reactivation. This is even more true in light of the fact that E2F-1, a well known apoptosis inducer, does not trigger the apoptotic cascade in myotubes (unpublished data).
Why TD muscle cells cannot be reactivated by E2F is not clear at this time. We have shown that E2F can elicit cyclin E overexpression in myotubes at least as well as E1A. However, in the case of E2F-expressing myotubes, cyclin E complexes are devoid of kinase activity. This ®nding might explain the absence of cyclin A expression in E2F-overexpressing muscle cells, since cyclin A transcription depends on cyclin Eassociated kinase activity (Zerfass-Thome et al., 1997) . As both cyclin E-and cyclin A-associated kinase activities are normally required for cell cycle progression (Ohtsubo et al., 1995; Pagano et al., 1992) , their absence might explain why our cells cannot enter S phase. However, it has been reported that E2F overexpression can drive some cell types to synthesize DNA in the absence of cyclin-dependent kinase activities (DeGregori et al., 1995) . Thus, the issue of the refractoriness of myotubes to E2F needs to be investigated further. In fact, not all TD cells are unresponsive to E2F, as it has been shown that ectopic E2F-1 expression can force TD, adult myocardiocytes into S phase and provoke apoptosis (Kirshenbaum et al., 1996) . Thus, lack of response to E2F is not a general property of all TD systems, suggesting that terminal dierentiation' is a general label for diverse cell states which have in common a strong resistance to cell cycle reentry. Our data suggest that such`mitotic aversion' might be mediated by dierent molecular mechanisms in diverse cell types.
Materials and methods
Cells
The mouse myoblast line C2C12 (Blau et al., 1985) was cultured as in Tiainen et al. (1996b) . Dierentiation was induced by starving the cells in serum-free (SF) medium. Cytosine b-D-arabinofuranoside (Ara-C, 50 mM) was added to SF medium to eliminate undierentiated cells. Within 72 h, Ara-C-puri®ed myotubes contained more than 90% of the nuclei in the culture. The C2Q16 clone of C2C12 becomes quiescent within 24 ± 36 h from the switching to SF medium. Primary muscle satellite cells (MSC) were isolated and cultured as described (Tiainen et al., 1996a) .
Plasmids
Reporter constructs: pGL3TATAbasic and pGL3TATA-basic6XE2F-Luc (derived from pGL3basic (Promega)) bear the E1B TATA box or six E2F DNA binding sites, respectively, upstream of a luciferase cDNA (kind gift of A Fattaey). The following expression vectors were used: bgalactosidase: pEQRSVb-Gal; luciferase: pSV2-luc; E2F-1: pCMVE2F-1 (Helin et al., 1993a) ; E2F-4-NLS: pCMVHAE2F-4-NLS (MuÈ ller et al., 1997); hemagglutinintagged DP-1 (Helin et al., 1993b) and mutant derivatives: pCMVHADP-1, pCMVHADP-1
, and pCMVHADP-1 127 ± 410 .
Viruses
Mutant or recombinant adenoviruses used for infections: dl520 expresses the 12S but not the 13S form of E1A; 12S.928 expresses the 12S form of a mutant E1A (Cys 124 to Gly); dl312 bears a deletion of essentially the entire E1A gene (Tiainen et al., 1996b) . AdE2F-1, AdE2F-2, AdE2F-4, and AdDP-1 (DeGregori et al., 1997) were kindly donated by J Nevins; J-pCA13 is an E1-deleted recombinant virus produced by recombining the pJM17 and pCA13 constructs (Microbix Biosystems). Infections were performed for 1 h in DMEM, after which the cells were shifted to SF or growth medium. AdE2F-1, AdE2F-2, AdE2F-4, and AdDP-1 were generally used at MOI 200 and dl520 at MOI 300, unless otherwise stated. Attempts at reactivating the cell cycle in myotubes were carried out in the presence of serum, to provide potentially necessary growth factors.
Transfections and assessment of DNA synthesis MSC myotubes were transfected with Lipofectin (Life Technologies) as described (Tiainen et al., 1996a) . To express foreign genes in C2C12 myotubes, proliferating myoblasts were seeded at 1.5610 5 cells/collagen-coated, 35-mm dish. One day later, the myoblasts were transfected using LipofectaMINE PLUS reagent (Life Technologies), according to a modi®cation of a published protocol (Trivedi and Dickson, 1995) . Best transfection eciency and survival were obtained with 1 ± 2.4 mg of total circular plasmid, 4 ± 6 ml of LipofectaMINE, and 6 ± 8 ml of PLUS reagent. The myoblasts were incubated for 3 h with the LipofectaMINE PLUS/DNA mixture and then either induced to dierentiate or, for parallel expression in myoblasts, maintained in growth medium. BrdUrd was added to dierentiated or proliferating cultures 24 or 36 h after transfection, respectively. The cultures were then ®xed 24 or 12 h later, respectively, and subjected to immuno¯uorescent detection of BrdUrd and either myosin heavy chain (MHC) or the exogenous gene product. In each dish, at least 100 MHC-positive or successfully transfected cells were scored to calculate the percentage of BrdUrd-positive cells. 
E2F transactivation assays
C2C12 myoblasts were transfected with the appropriate reporter and expression constructs and induced to differentiate immediately therafter. Myotubes were infected 72 h later and collected after a further 48 h. Luciferase and bgalactosidase (b-gal) assays were carried out by standard techniques. To con®rm that luciferase was expressed by myotubes, rather than the few, residual myoblasts, parallel transfections were analysed by immuno¯uorescence. Luciferase was never detected in myoblasts, but was strongly expressed in a fraction of the myotubes.
Immuno¯uorescence and Western blotting
Antibodies used: monoclonal antibodies (MoAbs) to BrdUrd and PCNA (DAKO); rabbit antisera to E2F-1, B-myb, cyclin A, cyclin E and cdk2 (Santa Cruz Biotechnology); MoAb to p27 (Transduction Laboratories); rabbit antiserum to p21 (kind gift of C Schneider); MoAb to pRb (PharMingen); rabbit antiserum to luciferase (Promega); rabbit antiserum (G Salvatori and G Cossu) or MoAb MF20 (Bader et al., 1982) to MHC; MoAb 12CA5 to hemagglutinin. Antisera to mouse or rabbit immunoglobulins were from ICN-Cappel. In immuno¯uorescence procedures, nuclei were counterstained with Hoechst 33258. Western blot samples were normalized so that lysates of cells possessing the same total number of nuclei were loaded in each well (to compensate for the higher protein content in myotubes, compared to myoblasts). Western blots were developed using the ECL kit (Amersham).
Northern blotting
Ara-C-puri®ed C2C12 myotubes and quiescent C2Q16 myoblasts were infected with the AdE2F-1 or dl312 virus.
Total cellular RNA was extracted from non-infected or infected myotubes and myoblasts at 24 or 48 h postinfection. Samples were separated, transferred, and hybridized according to standard protocols.
Immunoprecipitation and kinase activity assay
Cells were extracted for 30 min at 48C in 500 ml of lysis buer (20 mM HEPES, pH 7.9, 250 mM NaCl, 5 mM EDTA, 0.25% Nonidet P-40, 0.5 mM phenylmethylsulfonyl uoride, 0.5 mM sodium orthovanadate, 10 mM NaF, 1 mM dithiothreitol [DTT] , 2 mg/ml leupeptin, 1 mg/ml aprotinin). Cell lysates were brie¯y sonicated, centrifuged, precleared for 2 h with protein G-agarose (Santa Cruz Biotechnology), and incubated with protein G-agarose bound to the anti-cyclin E antibody. Immunoprecipitates were washed, resuspended in 50 ml of kinase buer (50 mM HEPES, pH 7.9, 10 mM MgCl 2 , 5 mM MnCl 2 , 1 mM DTT) supplemented with 1 mg of histone H1, 0.185 MBq of [g-32 P]ATP and 50 mM ATP, and incubated for 30 min at room temperature. The reactions were stopped with 56Laemmli buer; labeled proteins were resolved on an SDS-12.5% polyacrylamide gel and detected by autoradiography.
